Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sunitinib works in treating patients with metastatic
pancreatic cancer that progressed after first-line therapy with gemcitabine. Sunitinib may
stop the growth of pancreatic cancer by blocking blood flow to the tumor and by blocking some
of the enzymes needed for cell growth.